Alternative-protein and life-science manufacturers need affordable, scalable specialty proteins such as growth factors and enzymes, which are often expensive to produce conventionally.
R&D Focus
Recombinant proteins produced with insect pupae as bioreactors.
Innovative Solution
Uses insect pupae and a baculovirus-based expression platform to manufacture specialty enzymes, growth factors and other recombinant proteins.
Solution Effectiveness
The company states its Bilbao facility currently supports about 5 kg of recombinant protein output annually and has potential capacity above 20 kg per year.
Investment Funding
Last Funding Stage
Venture - Series Unknown
Total Funding Amount
18.24M
Last Funding Amount
2.15M
Last Funding Date
03-11-2023
Lead Investors
Columbus Venture Partners, BeAble Capital, Algenex, Sangha Capital, North South Ventures
Revenue
$10M to $50M
About
Cocoon Bioscience helps catalyze the expansion of bottlenecked industries like cultivated meat by manufacturing performance and growth factors and specialized enzymes for individual protein, nutrition, and healthcare applications.
Products
Product
Recombinant growth factors and specialty enzymes for cultivated protein and life-science applications.
Star Product
Insect-pupae recombinant-protein platform – designed to lower the cost and increase the scale of specialty-protein production.
Demo Product or Complete Product?
Commercial-scale facility opened in Bilbao in 2024; production and customer-supply scale-up stage.
Future Plan
Market Expansion
Scaling output at its Bilbao facility from current production toward more than 20 kg per year.
Investment Funding
Raised €15 million in Series A funding in March 2023, led by Columbus Venture Partners and Cleon Capital.
Awards and Recognitions
Certifications
The company states that its production strategy includes GMP-compliant manufacturing capability.
Something missing or incorrect on this page? Help us enrich this information
